Table-II.
Comparison of serum indicators between groups.
| Variables | TACE+lenvatinib group (n=46) | TACE group (n=57) | Z | P |
|---|---|---|---|---|
| AFP (ng/mL) | ||||
| Pre-treatment | 899.76(717.17-1017.50) | 891.47(765.61-990.50) | -0.229 | 0.819 |
| Post-treatment | 191.42(178.75-220.49)a | 310.00(296.20-367.00)a | -7.712 | <0.001 |
| ALT (U/L) | ||||
| Pre-treatment | 59.56(44.75-79.26) | 60.13(47.00-75.00) | -0.027 | 0.979 |
| Post-treatment | 45.21(26.75-65.56)a | 48.18(35.00-63.00)a | -0.808 | 0.419 |
| VEGF (ng/mL) | ||||
| Pre-treatment | 275.50(262.00-304.75) | 270.56(243.50-302.00) | -0.841 | 0.400 |
| Post-treatment | 137.50(122.75-168.83)a | 224.17(199.00-261.00)a | -8.715 | <0.001 |
Data were presented as median (range).
a
P < 0.001, compared with the same group pre-treatment.